TrialThe Lancet. Haematology2020

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.

Justin Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.